UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 14A

(RULE 14A-101)

INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.)

Filed by the Registrant ☑ Filed by a Party other than the Registrant o

Check the appropriate box:

o Preliminary Proxy Statement

o Confidential, for Use of the Commission Only (as permitted by Rule 14a-12))

o Definitive Proxy Statement

o Definitive Additional Materials

☑ Soliciting Material Pursuant to § 240.14a-11(c) or § 140.14a-12

BIOSCRIP, INC.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement)

Payment of Filing Fee (Check the appropriate box):

 \square No fee required.

o Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

- (1) Title of each class of securities to which transaction applies:
- (2) Aggregate number of securities to which transaction applies:
- (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

o Fee paid previously with preliminary materials.


o Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:



Safe Harbor

This presentation includes forward-looking statements regarding the proposed acquisition and related transactions that are not historical or current facts and deal with potential future circumstances and developments, in particular information regarding growth opportunities, expected synergies from the acquisition, and whether and when the transactions contemplated by the merger agreement will be consummated. Forward-looking statements are qualified by the inherent risk and uncertainties surrounding future expectations generally and may materially differ from actual future experience. Risks and uncertainties that could affect forwardlooking statements include: the failure to realize synergies as a result of operational efficiencies, purchasing volume discounts, cross-selling of services, streamlined distribution and general and administrative reductions in the timeframe expected or at all; unexpected costs or liabilities; the result of the review of the proposed transaction by certain regulatory agencies, and any conditions imposed in connection with the consummation of the transaction; approval of issuance of BioScrip's stock in connection with the transaction by the stockholders of BioScrip and satisfaction of various other conditions to the closing of the transaction contemplated by the merger agreement; and the risks that are described from time to time in BioScrip's reports filed with the Securities and Exchange Commission (the "SEC"), including BioScrip's annual report on Form 10-K for the year ended December 31, 2008 and quarterly report on Form 10-Q for the quarter ended September 30, 2009, as amended. This press release speaks only as of its date, and BioScrip disclaims any duty to update the information herein.

bio scrip

Safe Harbor (cont'd)

Additional Information and Where to Find it

- BioScrip, Inc. intends to file with the Securities and Exchange Commission (the "SEC") a proxy statement regarding the issuance of stock in connection with the proposed transaction. The proxy statement will be mailed to the stockholders of BioScrip. INVESTORS AND STOCKHOLDERS ARE ADVISED TO READ THE PROXY STATEMENT AND OTHER RELEVANT MATERIALS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT BIOSCRIP AND THE PROPOSED TRANSACTION. Investors and stockholders may obtain free copies of these documents (when they are available) and other documents filed with the SEC at the SEC's web site at www.sec.gov. In addition, the documents filed by BioScrip with the SEC may be obtained free of charge by contacting BioScrip, Inc., Corporate Secretary, 100 Clearbrook Road, Elmsford, NY 10523 or contacting BioScrip, Inc. Corporate Secretary at 914-460-1600.
- Participants in the Solicitation
- BioScrip and its officers and directors may be deemed to be participants in the solicitation of proxies from BioScrip's stockholders with respect to the issuance of stock in connection with the proposed transaction. Information about BioScrip's executive officers and directors and their ownership of BioScrip's stock is set forth in the proxy statement for BioScrip's 2009 Annual Meeting of Stockholders, which was filed with the SEC on March 27, 2009. Investors and stockholders may obtain more detailed information regarding the direct and indirect interests of BioScrip and its respective executive officers and directors in the proposed transaction by reading the preliminary and definitive proxy statements regarding the issuance of stock in connection with the proposed transaction, which will be filed with the SEC.

bio a scrip

BIOSCRIP, INC. TO ACQUIRE CRITICAL HOMECARE SOLUTIONS -Platform Expands Geographic Footprint; Creates Leading Independent, Specialty Pharmacy and Home Infusion Provider-

- BioScrip will acquire CHS for \$343.2 million in cash and stock and will issue 3.4 million warrants to CHS shareholders
- Creates the leading, independent specialty pharmacy and home infusion provider
 - National network of specialty and home infusion pharmacies in 28 states
 - 1,000+ payer relationships
 - Over 100 points of service
- On a pro forma basis, the combined company generated \$1.6 billion of revenue and \$73.4 million in adjusted EBITDAO for the trailing twelve month period ending September 30, 2009
- Transaction expected to be accretive to 2010E cash EPS

bio & scrip

Patients

Managed Care Organizations

Pharmaceutical Manufacturers

Physicians, Hospitals, Clinics

Distribution

Community Infusion Mail

Management


Adherence Compliance Retention

Access - Quality - Cost Specialty pharmacy services

Long-term Strategic Goals

- Build clinical leadership across all technologies: infusion, oral, injectibles, nursing
- Expand our national footprint: high-touch/high-feel model
- Grow revenue, expand margins and operating income
- Adherence, compliance and retention model improves quality of care and controls overall medical costs and reduce hospitalizations


Overview of Critical Homecare Solutions




Key Benefits of the Transaction

- Ability to cross-sell all services on a national basis, enabling accelerated pull-through opportunities
 - 140 field sales professional
- Expanded national footprint with strong regional and local management
- Focus on traditional higher margin therapies that will expand overall margins
- Broadened clinical services organization and expertise
- Comprehensive nursing component required to better manage the chronically ill
- Access to additional 450 payer agreements
- Annualized cost synergies of \$5 \$7 million






BioScrip is an integrated solution...




Specialty Market Opportunity

- \$60 billion industry, growing at 15% 20% per annum
 - High-cost, chronic care therapies with side effects creates need to clinically manage these patients
 - Market growth driven largely by increased utilization due to existing and new technologies and demographics
- Specialty pharmacy cost ranges from \$18,000 \$350,000 per patient/year
- Specialty pharmacy medication launches represent nearly half of medications in late-stage development with a high percentage requiring infusion
- Oral, injectible and infused technologies on the market and in development requires high-tech clinical management and administration services
- Accelerated utilization of alternate sites for administration

Specialty Pipeline Focus: 2010 and beyond



Source: PhRMA 2008 Report: Medicines in Development



Convergence of Specialty Pharmacy and Home Care


BioScrip


Fully Integrated Service Model

Specialty Pharmacy	Specialty Service Center	Home Infusion Pharmacy	Home Nursing
•State-of-the-art pharmacy and clinical management programs for improved outcomes	•Full-scale inventory and adjunctive products •Advanced drug utilization review and	•Full-scale medication and service provider •Nursing care plans, documentation &	•Skilled Nursing and other therapy services to adults and pediatric patients suffering from various chronic or
•Enhanced PA, UM and VOB methodologies	patient counseling •Counseling, testing	 reporting Patient and caregiver 	serious health conditions
•Direct-to-patient and	and referral, with strong linkage to community	training	•Hospice
direct-to-physician services	medical care, treatment and prevention services	 Joint Commission accredited (JCAHO) 	•Home Health
			Private duty nursing

 Pharmacy and medical claims reimbursement 	Horizontal Capabilities	 Inventory availability and product distribution Access to specialty trained pharmacists and nurses Medication management Utilization and formulary management support Physician and patient coordination / partner collaboration Nursing and social work support services Customized care plans and clinical management Home nursing services coordination
	Horiz	•

BioScrip and CHS





Proposed Acquisition of Critical Homecare Solutions Summary of Key Transaction Terms

Acquiror	BioScrip, Inc.
Target	Critical Homecare Solutions ("CHS")
Consideration	Cash: \$242.0 million (includes an estimated \$132.0 million to repay CHS debt) Stock: 12.94 million shares (\$101.2 million based on last closing price) Warrants: 3.40 million (\$10.00 strike price with a 5-year term)
CHS Shareholder Pro Forma Ownership	Approximately 24%
Financing Commitment	Jefferies Finance LLC
Timing	Expected closing: March 31, 2010
Board of Directors	2 Board seats
	bio @ scrip

Pro Forma Combined Financial Summary

LTM as of September 30, 2009

- Pro forma LTM revenue of \$1.6 billion
- Pro forma LTM Adjusted EBITDAO of \$73.4 million
- Estimated at Close
 - \$27.0 million in cash
 - \$325 million in total debt
 - Net debt / pro forma LTM Adjusted EBITDAO of 4.1x

Pro Forma Guidance and Merger Impact

Pro Forma Company Overview

2010 Guidance (based on 9 months of CHS, assuming closing on March 31, 2010)
Revenue \$1,670 - \$1,730 billion
Gross Profit \$267 - \$277 million
EBITDAO \$67 - \$71 million
Transaction expected to be accretive to 2010 cash EPS and slightly dilutive on a GAAP basis; cash and GAAP EPS accretion expected after 2010
Attractive combined free cash flow profile with longer-term leverage target of ~2.0x

BioScrip, Inc. Investor Presentation

January 2010 Jefferies & Company, Inc. 2010 Global Healthcare Services Conference

bio 🖗 scrip

NASDAQ: BIOS